Core Viewpoint - The Hong Kong Dividend ETF (工银, 159691) experienced significant net redemptions, indicating a trend of outflow from this fund, which may reflect investor sentiment and market conditions [1][2]. Fund Performance - As of February 3, the latest scale of the Hong Kong Dividend ETF is 85.4 billion yuan, with a net outflow of 28.23 million yuan on that day, representing 0.33% of the previous day's scale [1]. - Over the past five days, the fund faced net redemptions totaling 68.26 million yuan, ranking 15th out of 212 in cross-border ETF net outflows [1]. - In the last ten days, the total net redemptions reached 202 million yuan, ranking 7th out of 212 [1]. - Over the past 20 days, the fund saw net redemptions of 332 million yuan, ranking 8th out of 212 [1]. Fund Size and Liquidity - The current share count of the Hong Kong Dividend ETF is 6.282 billion shares, with a scale of 85.4 billion yuan, showing a 3.80% decrease in shares and a 1.24% increase in scale since December 31, 2025 [2]. - The cumulative trading amount over the last 20 trading days is 6.501 billion yuan, with an average daily trading amount of 325 million yuan [2]. - Year-to-date, the cumulative trading amount is 7.151 billion yuan, with an average daily trading amount of 325 million yuan [2]. Fund Management - The current fund managers are Liu Weilin and He Shun, with Liu managing since March 30, 2023, achieving a return of 36.96%, while He is set to manage from May 30, 2024, with a return of 14.67% [2]. Top Holdings - The fund's top holdings include: - China National Offshore Oil Corporation (14.55% holding) - China Shenhua Energy (9.65% holding) - China Pacific Insurance (8.90% holding) - China Hongqiao Group (7.68% holding) - CLP Holdings (7.53% holding) - WH Group (7.36% holding) - Power Assets Holdings (6.21% holding) - Haier Smart Home (3.50% holding) - People's Insurance Company of China (3.42% holding) - CSPC Pharmaceutical Group (3.41% holding) [2].

Core Insights - The report from Dongfang Securities highlights the significant commercial value of extrahepatic delivery technology, driven by MNCs' increasing interest and the rapid development of domestic companies in multi-target drugs and extrahepatic delivery platforms [1][2][3] Group 1: Market Dynamics - Frequent transactions in small nucleic acids indicate rising global recognition of domestic drugs, exemplified by recent strategic collaborations involving Shengyin Biotech and major pharmaceutical companies like Eli Lilly and Roche, which include upfront payments and milestone payments totaling up to $12 billion and $15 billion respectively [1] - MNCs are shifting focus from liver-targeted delivery technologies to extrahepatic delivery systems, targeting organs such as fat, muscle, central nervous system, heart, and kidneys, which could address significant unmet clinical needs [2] Group 2: Domestic Innovation - Domestic companies have accumulated substantial experience in chemical modifications and liver-targeted delivery technologies for small nucleic acids, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [3] - The proactive development of extrahepatic delivery platforms and multi-target small nucleic acid drug platforms positions domestic firms at the forefront globally, attracting MNCs' interest [3] Group 3: Investment Opportunities - Potential investment targets include companies such as Yuyuan Pharmaceutical, Frontier Biotech, Fuyuan Pharmaceutical, Chengdu Xian Dao, and others, which are positioned to benefit from the growing market for small nucleic acid drugs [4]

Market Overview - The Hang Seng Index closed at 26,835 points, up 0.2%, while the Hang Seng China Enterprises Index closed at 9,053 points, down 0.3%[1] - Total turnover in the Hong Kong stock market was HKD 335.2 billion, a decrease of 3.7% from the previous day's HKD 347.9 billion[1] - Sector performance varied, with materials, conglomerates, and industrial indices rising by 4.4%, 2.9%, and 2.8% respectively, while information technology, consumer discretionary, and telecommunications fell by 1.7%, 0.6%, and 0.1% respectively[1] Stock Performance - Leading blue-chip stocks included CSPC Pharmaceutical (1093 HK) and New Oriental (9901 HK), which rose by 8.1% and 6.4% respectively[1] - Kuaishou (1024 HK) and Baidu Group (9888 HK) were among the biggest losers, falling by 4.6% and 3.6% respectively[1] Industry Dynamics - The automotive sector is projected to see China National Heavy Duty Truck Group's total sales reach 450,000 units in 2025, a year-on-year increase of 25%[4] - The company expects to maintain a 39% market share, with heavy truck sales exceeding 300,000 units, leading global sales rankings[4] - The new energy heavy truck segment is anticipated to grow explosively, with a year-on-year increase of 230% expected in 2025[4] Pharmaceutical Sector - The pharmaceutical sector saw significant gains, with Insilico Medicine (3696 HK) surging 14.5% after announcing a milestone payment of HKD 39 million for a clinical trial[5] - The total collaboration agreement for the project is valued at USD 550 million, indicating potential for further milestone revenues as trials progress[5] Macro Economic Indicators - Hong Kong's retail sales in December 2025 increased by 6.6% year-on-year, slightly higher than the 6.5% increase in November[3] - South Korea's January CPI rose by 2.0%, lower than the 2.3% in December and below market expectations of 2.1%[3]

每周 一 景 ：甘孜藏族自治州四川省贡嘎雪山 点击右上角菜单，收听朗读版 【基金 】 国泰海通证券2月基金投资策略 基金投资策略 股混基金： 从基金投资的角度来看，在成长主线下，价值和成长风格中均具备结构性投资机会的市场格局或将延续，因此我们建议后续基金配置在整体维持 均衡风格的前提下，适度偏向成长，并且关注基金经理的选股和风控能力，重视主投科技领域基金，兼顾周期、金融等资产。 指数主题基金： 我们从基本面景气度、超预期水平、量价水平和资金流强度四个维度出发，构建行业轮动模型，2月最新高景气度行业分别为基础化工、建筑 材料、环保、石油石化、通信和钢铁，结合ETF产品的流动性和相关性，我们构建的ETF行业轮动投资组合。 债券基金： 从基金投资角度来看，建议关注久期灵活的利率债和重配高流动性信用债的产品。此外，随着权益市场回暖，我们认为固收+基金同样具备一定配 置价值，建议持续关注。 QDII和商品型基金： 全球地缘政治局势的不确定性上升以及各国央行持续购金有利于支撑长期金价中枢，从长期投资和避险投资的角度来看，我们认为可适 当配置黄金ETF，但趋势配置者短期需要谨慎。美国经济韧性较强，内生性通胀粘性逐渐减弱，投 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [6] Core Insights - The report highlights the significant commercial value of extrahepatic delivery technology for small nucleic acid drugs, which is expanding from liver diseases to multiple disease areas. Domestic companies are rapidly developing multi-target drugs and extrahepatic delivery platforms, which are expected to accelerate the release of potential clinical value [3][8] - The report emphasizes that multinational corporations (MNCs) are intensifying their focus on next-generation delivery platforms, moving from "liver validation" to "multi-organ expansion." This shift is crucial as it addresses unmet clinical needs in various tissues such as fat, muscle, central nervous system, heart, and kidneys [8] - The report indicates that 2026 is a pivotal year for small nucleic acid therapies, with domestic innovative drugs expected to become core assets for transactions. Domestic companies have accumulated rich experience in chemical modifications and liver-targeted delivery technologies, covering high-value areas such as hyperlipidemia, hypertension, hepatitis B, and weight loss [8] Summary by Sections Industry Overview - The report focuses on the pharmaceutical and biotechnology industry in China, specifically on small nucleic acid drugs and their evolving delivery technologies [5][6] Investment Recommendations and Targets - The report lists several investment targets, including: - YK Pharma (688658, Buy) - Hengrui Medicine (600276, Buy) - Xinda Biopharma (01801, Not Rated) - Other companies such as Chengdu XianDao (688222, Not Rated), Reborn Biotech (06938, Not Rated), and others [3]

Market Overview - The Hong Kong stock market experienced volatility, with the Hang Seng Index closing up 0.22% at 26,834.77 points, while the Hang Seng Tech Index fell 1.07% to 5,467.26 points, reflecting a mixed performance across sectors [1] - Huatai Securities noted that the recent "Wash Trade" led to a global risk-off sentiment, causing liquidity pressure and a decline in commodities and Asian markets, but they believe the adjustment is more technical and emotional, with a positive medium-term outlook for Chinese assets [1] Blue-Chip Stocks Performance - Tencent (00700) saw a significant drop of 2.92%, closing at 581 HKD, contributing to a decline in the Hang Seng Index by 59.56 points, influenced by rumors regarding potential tax adjustments on high-margin sectors like financial services and internet value-added services [2][7] - Other notable blue-chip movements included a rise of 8.09% for CSPC Pharmaceutical Group (01093) and a decline of 2.42% for both Semiconductor Manufacturing International Corporation (00981) and China Unicom (00762) [2] Sector Highlights - The technology sector faced pressure due to tax rumors, with Tencent dropping over 6% at one point, while gold and silver prices rebounded significantly, with gold rising over 5% to 4,916.6 USD/oz [3][4] - The commercial aerospace sector gained attention with SpaceX's acquisition of xAI, valued at approximately 1.25 trillion USD, which is expected to benefit the domestic space photovoltaic industry [5] - The engineering machinery sector showed resilience, with a reported 13.2% year-on-year increase in export trade, driven by strong demand for excavators [7] Notable Stock Movements - Ying Si Intelligent (03696) reached a new high, closing up 14.52% at 69 HKD, following milestone payments related to its clinical trial project [8] - CIMC Group (000039) also performed strongly, closing up 14.98% at 9.98 HKD, with significant deliveries in data center business and a robust order book in the marine engineering sector [9] - The AI model companies, MINIMAX (00100) and Zhizhu (02513), saw increases of 10.98% and 8.28% respectively, following the release of new models [9]

Market Overview - The Hong Kong stock market experienced volatility, with the Hang Seng Index closing up 0.22% at 26,834.77 points, while the Hang Seng Tech Index fell 1.07% to 5,467.26 points, reflecting a mixed performance across sectors [1] - Huatai Securities noted that the recent "Wash Trade" triggered a global risk-off sentiment, leading to liquidity pressures and declines in commodities and Asian markets, but they believe the adjustment is more technical and emotional, with a positive medium-term outlook for Chinese assets [1] Blue-Chip Stocks Performance - Tencent (00700) saw a significant drop of 2.92%, closing at 581 HKD, contributing to a decline in the Hang Seng Index by 59.56 points, influenced by rumors regarding potential tax adjustments targeting the financial and internet sectors [2][7] - Other notable blue-chip movements included a rise of 8.09% for CSPC Pharmaceutical Group (01093) and a decline of 2.42% for both Semiconductor Manufacturing International Corporation (00981) and China Unicom (00762) [2] Sector Highlights - The technology sector faced pressure due to tax rumors, with Tencent dropping over 6% at one point, while gold and silver prices rebounded significantly, with gold rising over 5% to 4,916.6 USD/oz and silver increasing by over 9% [3][4] - The commercial aerospace sector gained attention with SpaceX's acquisition of xAI, valued at approximately 1.25 trillion USD, which is expected to benefit the domestic space photovoltaic industry [5] - The engineering machinery sector showed resilience, with a reported 13.2% year-on-year increase in export trade, driven by strong demand for excavators [7] Notable Stock Movements - Ying Si Intelligent (03696) reached a new high, closing up 14.52% at 69 HKD, following milestone payments related to its clinical trial project [8] - CIMC Group (02039) also performed strongly, closing up 14.98% at 9.98 HKD, with significant deliveries in its data center business and a robust order book in its marine engineering segment [9] - MiniMax (00100) and Zhiyuan (02513) both saw gains, with increases of 10.98% and 8.28% respectively, following the release of new AI models [10]

Group 1 - The core viewpoint is that various institutions maintain "buy" ratings for different companies, highlighting their growth potential and strategic partnerships [1][2][3][4][5][6][7][8][9][10] Group 2 - China-based pharmaceutical company, Stone Pharmaceutical Group, has entered a significant $18.5 billion strategic collaboration with AstraZeneca, focusing on long-acting GLP-1/GIPR dual-target peptides and multiple obesity/diabetes pipelines, enhancing its AI-driven drug discovery capabilities [1][2] - Baidu Group's cloud business has shown a 10% year-on-year growth in Q4, driven by intelligent cloud infrastructure, with AI-native marketing services now covering 70% of search result pages [3] - Sunny Optical Technology is projected to see a 70-75% increase in net profit by 2025, benefiting from improved ASP and gross margin in mobile lenses and modules [4] - InSilico Medicine has secured over HKD 930 million in cardiovascular metabolic collaborations, continuing its partnerships with major pharmaceutical companies, and has produced 27 preclinical candidate molecules through its Pharma.AI platform [5][6] - Kuaishou Technology is enhancing its platform with advanced AI models, which are expected to improve user engagement and profitability [6] - Decon Agriculture is expected to achieve a target price of HKD 87, with a stable cost structure and leading efficiency in pig farming [7] - Dongfang Zhenxuan has exceeded profit expectations by 68% in the first half of FY26, with self-operated product GMV rising to 52.8% [8] - Hang Lung Properties is experiencing a recovery in retail sales, with Q3/Q4 growth rates of 10% and 18%, respectively, and an improved tenant mix [10]

国泰海通发布研报称，在英国首相访华期间，阿斯利康宣布计划在中国投资150亿美元，为中国及全球 患者提供尖端治疗方案。该行认为，本次投资再次证明在中国工程师红利及生物医药能力的持续验证 下，MNC对于中国本土研发能力及中国市场的兴趣和认可。 国泰海通主要观点如下： 在英国首相访华期间，阿斯利康宣布计划在中国投资150亿美元 近日，英国首相斯塔默开启为期4天的访华行程，随同斯塔默访问的有超50家企业高管和机构代表。其 中，阿斯利康全球首席执行官苏博科、葛兰素史克董事会主席司明麒作为英国医药产业的代表随团访 华。这项投资用于扩大药品制造和研发。这项投资将充分利用中国卓越的科学实力、先进的制造能力以 及中英医疗健康生态系统合作优势，为中国及全球患者提供尖端治疗方案。 150亿美元投资主要用于细胞疗法+RDC药物 鉴于中国在新型治疗模式(new modalities)领域的先进科学水平，此项投资将大幅提升公司在细胞疗法和 放射性偶联药物方面的能力，以推动其广泛而多样化的研发管线，帮助癌症、血液疾病和自身免疫性疾 病等患者。这些投资涵盖整个价值链，从药物发现、临床开发到生产制造，并通过与领先生物技术公司 (包括AbelZ ...

Core Viewpoint - The report from China Merchants Securities (Hong Kong) maintains a "Buy" rating for CSPC Pharmaceutical Group (1093.HK) with a target price of HKD 13.93, highlighting the company's strategic partnership with AstraZeneca valued at USD 1.85 billion, which validates the value of its AI-driven and long-acting peptide platform [1] Group 1: Financial Performance - The company has seen continuous realization of BD (Business Development) revenue, indicating strong financial performance [1] - For the first nine months of 2025, the core business has shown a quarter-on-quarter improvement, with a decrease in the sales expense ratio [1] - The DCF (Discounted Cash Flow) valuation has been adjusted upwards, reflecting enhanced visibility of earnings driven by BD [1] Group 2: Strategic Developments - The partnership with AstraZeneca is a significant milestone, emphasizing the potential of the company's innovative platforms [1] - The focus on high-intensity R&D investment remains a priority for the company, supporting its long-term growth strategy [1]